Thrombotic thrombocytopenic purpura natural history, complications and prognosis

Thrombotic thrombocytopenic purpura Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Thrombotic thrombocytopenic purpura from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Peripheral Smear
Direct Coombs Test
von Willebrand Factor-cleaving Protease Activity
X-ray
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Thrombotic thrombocytopenic purpura natural history, complications and prognosis On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Thrombotic thrombocytopenic purpura natural history, complications and prognosis All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Thrombotic thrombocytopenic purpura natural history, complications and prognosis
CDC on Thrombotic thrombocytopenic purpura natural history, complications and prognosis
Thrombotic thrombocytopenic purpura natural history, complications and prognosis in the news
Blogs on Thrombotic thrombocytopenic purpura natural history, complications and prognosis
Directions to Hospitals Treating Thrombotic thrombocytopenic purpura
Risk calculators and risk factors for Thrombotic thrombocytopenic purpura natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Prognosis

The mortality rate is approximately 95% for untreated cases, but the prognosis is reasonably favorable (80-90%) for patients with idiopathic TTP diagnosed and treated early with plasmapheresis.

Approximately one-third of patients experiencing a TTP episode have a relapse within 10 years following their first attack.

Secondary TTP still has a dismal prognosis, with mortality rates despite treatment being reported as 59% to 100%.